Lifebrain

About Lifebrain

Lifebrain operates as a prominent provider of clinical laboratory testing services, primarily centered in the Italian market. The company was established in February 2013 by Professor Michael Havel, a former cardiac surgeon, and Bernhard Auer, who assumed the role of CFO. Dr. Havel's entrepreneurial journey began prior to Lifebrain, having founded and successfully exited Futurelab, another major European laboratory group, which provided him with substantial experience in consolidating the fragmented lab diagnostics market.

The company's business model is anchored in a "buy-and-build" strategy, aggressively acquiring and integrating smaller laboratories across Italy to create a large, standardized network. This strategy proved effective, and by 2018, the private equity firm Investindustrial acquired a majority stake to fuel further expansion. A significant milestone occurred in October 2021, when Cerba HealthCare, a major European player in medical diagnostics, completed its acquisition of Lifebrain for approximately €1.2 billion, making Cerba the market leader in Italy. This acquisition integrated Lifebrain into a global network spanning 47 nations with over 1,140 laboratories.

Lifebrain's revenue is generated by performing a vast array of diagnostic tests for a diverse client base that includes individual private patients (B2C) and business-to-business (B2B) clients such as private and public hospitals and other healthcare facilities. The service portfolio is comprehensive, covering routine and specialty tests across key areas of laboratory medicine, including clinical chemistry, hematology, immunochemistry, microbiology, molecular biology, cytology, and pathology. The company operates through a 'Hub and spoke' system, where samples are collected from numerous points and processed in centralized, high-tech hub laboratories, ensuring efficiency and standardized quality across its extensive network.